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Abstract 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting a range 
of cognitive faculties, for which there is currently no treatment, save for ameliorative strategies. 
This disease primarily affects the elderly, and is the leading cause of dementia among this group. 
Out of an estimated 5.4 million Americans with AD this year, 5.2 million are over the age of 65. 
With the amount of people aged 65 and older increasing as the Baby Boomer generation ages, 
AD will become an increasingly dire burden. As we face this growing issue, research into both 
its causes and more sensitive and accurate diagnostic tools abounds.
1
 This research progresses in 
tandem with efforts to more accurately describe, identify, and understand a prodromal, 
transitional state between normal cognition and Alzheimer’s dementia called Mild Cognitive 
Impairment (MCI). MCI comprises a number of sub-types, one of which (amnestic MCI) having 
a marked association with later progression to frank AD.
2
 This introduction will offer a summary 
of these conditions and the research into their etiology, clinical criteria, and improved methods of 
earlier detection. Emphasis will later be placed on the biology of dendritic spines, including the 
upstream regulators of their development, and their relation to AD and MCI.  
Alzheimer’s disease  
Causes: I. Amyloid Cascade Hypothesis, II: Alternative hypotheses 
 In 1906, Alois Alzheimer presented the first description of the dementia now known as 
Alzheimer’s disease. After following the clinical development of the patient, Auguste D, 
Alzheimer identified upon microscopic analysis of her stained brain tissue anomalous deposits 
which he termed “miliary foci” and neurofibrils. These two pathological findings, now known to 
be senile plaques composed of amyloid-β (Aβ) and neurofibrillary tangles (NFTs) of the tau 
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protein respectively, were presented by Alzheimer in relation to Auguste’s clinical displays of 
cognitive decline, and were quickly accepted as both characteristic and somehow causative of the 
disease’s neurodegeneration and its resultant impact on cognitive faculties. Over the past century, 
further study has produced a general hypothesis for the pathogenesis of Alzheimer’s disease 
termed the amyloid beta cascade, which implicates the accumulation of the Aβ peptide as the 
primary initiator of a sequence of cellular and sub-cellular events which eventually manifest in 
dementia. While this (or at least parts of it) remains the most widely accepted etiological 
mechanism, evidence has accumulated which suggests that the true process might be more 
heterogeneous, comprising a number possible avenues which converge at the precipitation of 
dementia, for which the pathological findings of senile plaques and NFTs are not as much 
primary instigators as they are coincident with and perhaps subsequent to different processes.
3
 In 
the following sections, the amyloid cascade hypothesis will first be described and its evidential 
support summarized, after which other hypotheses will be likewise delineated.  
I: Amyloid Cascade Hypothesis 
 The generation of senile plaques and neurofibrillary tangles has long been a focus of 
research, and much has been learned about how these structures arise. Senile plaques are 
aggregates of primarily the protein amyloid-β, itself produced by the cleavage of a protein called 
amyloid precursor protein (APP) by the protease γ-secretase.3,4 The sequencing of senile plaques 
in 1984, which revealed Aβ as their primary constituent, coupled with the identification of 
mutations in the APP gene encoding APP as causative of familial AD in 1991 laid the 
groundwork for what is now called the amyloid cascade hypothesis by appearing to clearly indict 
Aβ deposition as the basic initiator of the disease.4 The two biggest players in this hypothesis are 
senile plaques and NFT’s, so it is natural to begin with an introduction to these components. 
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 Observational evidence for the accumulation of Aβ instigating or supporting the onset of 
AD has been abundant, comprising Alzheimer’s own findings a century ago, as well as the 
discovery of mutations in genes directly related to Aβ production that cause early onset, familial 
AD. These genes include APP and presenilin-1 and presenilin-2. Mutation in APP invariably 
produced early onset AD, thought the exact mechanism by which this occurs is unknown. 
Presenilin-1 and -2 both constitute a portion of γ-secretase, a proteolytic enzyme that cleaves Aβ 
from APP prior to its export. A number of mutations in presenilin-1 and -2 have been 
demonstrated as causative of early onset AD, and in fact cause the majority of early onset 
familial AD. While the disease process in late onset, sporadic AD (absent the aforementioned 
mutations) is more complicated than the early onset disease, these mutations constitute strong 
evidence for Aβ being an integral player, and have informed much of the study into Aβ toxicity 
and its role in sporadic AD.
15 
As Aβ peptide fragments are liberated from APP by γ-secretase, they begin to 
agglomerate extracellularly into dimers, trimers, and greater-n oligomers. The resultant senile 
plaques have been shown to primarily associate with the postsynaptic components of synapses, 
the majority of which are dendritic spines. Marked decreases (in general) in synaptic and spine 
integrity have been observed. While the exact mechanism of this selective toxicity towards 
postsynaptic structure and function remains unknown, a number of experimental models have 
shown Aβ plaques, and to a greater extent, smaller oligomeric soluble fragments, to mediate their 
effects via certain postsynaptic receptors, including prion protein, metabotropic glutamate 
receptors (mGluRs), and NMDA receptors.
5
 NMDA receptors are of particular import given their 
roles in excitatory glutamate neurotransmission and participation in pathways affecting 
mitochondrial function.  Studies have shown that Aβ oligomer association with NMDA receptors 
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results in the activation of signaling pathways leading to an increase in the production of reactive 
oxygen species (ROS), which are ultimately responsible for impaired neuronal function and cell 
death. Furthermore, dysregulation of these receptors and their downstream effects mediating 
synaptic plasticity is observed as a result of exposure to Aβ oligomers.6,7 Finally, studies have 
revealed a pathway in which the density of post-synaptic NMDA receptors is reduced as a result 
of a biochemical cascade ending in the endocytosis of NMDA receptors; this cascade initiated by 
the binding of Aβ oligomers to α7-nicotinic receptors.8 
 In addition to the presence of senile plaques, neurofibrillary tangles (NFTs) are likewise 
considered a hallmark characteristic of AD. NFTs are abnormal polymers of the microtubule 
associate protein tau (MAPT). Normally involved in stabilizing microtubules by associating with 
tubulin, in AD the tau proteins are found to be hyperphosphorylated, a condition in which they 
dissociate from tubulin and conglomerate ultimately into NFTs.
9
 In the normal brain, tau is 
localized primarily to the axon, where it contributes to axonal transport through its association 
with and maintenance of microtubule structures, though it is also present in dendrites. As tau 
becomes hyperphosphorylated and its associations transition from mictrotubule structures to 
NFTs, they apparently migrate to the somatodendritic domain. Studies have also established 
normal tau as a potentially important player in the dendritic spine, contributing to the 
maintenance of scaffolding proteins (including microtubules) that help regulate spine formation 
and plasticity. Additionally, pathogenic tau (hyperphosphorylated) has been shown to instigate a 
pathway that ultimately modifies NMDA receptors to be more susceptible to Aβ-meditated 
synaptotoxicity. Therefore, tau has been implicated in the disease process both by its loss of 
beneficial functions and its gained function in facilitating Aβ synaptotoxicity.5 
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The amyloid cascade hypothesis argues that a series of events beginning with Aβ 
accumulation, and in which the hyperphosphorylation and accumulation of MAPT into NFTs are 
the most prominent of a number of related events, ultimately ends in neurodegeneration and 
dysfunction.
3
 As described above, Aβ oligomers cause a number of these downstream synaptic 
issues, including excitotoxicity, alterations of membrane receptor stoichiometry (in particular of 
NMDARs), and dysregulation of postsynaptic signaling leading to oxidative stresses.
5,8
 Also 
central to this sequence is the role of neuroinflammation, a conclusion that has been somewhat  
contentious, as described below.  
While some epidemiological studies have credited the long term use of non-steroidal anti-
inflammatory drugs (NSAIDs) with reducing the risk for developing AD, others have found 
contradictory results. 
10,11 
Proliferation of microglia (primary, glial immune cells of the central 
nervous system) and astrocytes (glial supportive cells in the central nervous system) in 
association with senile plaques has also been observed, with microglial cells testing positive for 
numerous proinflammatory factors. These factors are known to include species that can initiate 
neuronal death, including prostaglandins and nitric oxide. Furthermore, microglia and astrocytes 
are capable of sensing Aβ through a number of toll-like receptors (TLR2, TLR4, and TLR9) 
expressed on their surfaces. Consensus on the ultimate results of microglial activation via this Aβ 
detection has been elusive, as different studies have suggested that microglial activation may 
facilitate their recognition and clearance of senile plaques and thus proffer neuroprotection, 
while others support the notion that their activation induces immuno-inflammatory responses 
that further damage neurons.
12
 Recent studies have further supported the notion that microglia 
play a neuroprotective role in at least some capacity. At least two studies involving the 
administration of factors that initiate the production and recruitment of microglia (primarily from 
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the bone marrow as opposed to those endogenous to the brain) have reported reduced 
amyloidosis (Aβ deposition) and cognitive decline in mouse models of AD.13,14 While there 
remains no clear consensus of the role of inflammatory and immune responses in AD, it is clear 
that these processes are unlikely to represent a black and white mechanism of exclusive 
protection or harm, and the inducement of inflammation by Aβ nonetheless remains in general a 
canonical event in the amyloid cascade hypothesis.  
To summarize, the most comprehensively described hypothesis to explain the progression 
of Alzheimer’s disease is that of the amyloid cascade. Chronologically, Aβ deposition as a result 
of either greater production due to genetic mutations (APP, presenilin-1 and -2) or due to some 
other undefined failure to clear Aβ fragments adequately, initiates early synaptic dysfunction, 
followed by further plaque formation; inflammation via astrocytic and microglial activation; 
signal cascade dysregulation leading to oxidative stress, changes in post-synaptic receptors, and 
the hyperphosphorylation of MAPT and subsequent production of NFTs; and ultimately neuronal 
death as a result of the continuation and exacerbation of the above processes. Despite its 
widespread support, there remain some difficulties with the amyloid cascade hypothesis. Perhaps 
foremost among these is that correlation between senile plaques and AD is not in itself very 
descriptive; i.e., the amount of senile plaque pathology is a poor measure of the severity and 
progression of AD symptoms, and the finding of Aβ pathology in non-demented individuals 
further stresses this disconnect. Adding to the uncertainty are conflicting results from studies 
investigating various predictions made by the hypothesis regarding the effects of the insoluble 
senile plaques, though the hypothesis has adapted to incorporate the effects of the smaller soluble 
oligomers of Aβ described above.16 While the finer points of this hypothesis (such as the role of 
inflammation, also described above) still require further elucidation, the majority of attempts to 
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synthesize current findings in AD produce sequences resembling the amyloid cascade; the most 
variability from model to model concerns the earliest phases of the disease and the participation 
of neuroinflammation.
3
 
II: Alternative Syntheses 
 The association of amyloid deposition with the development of Alzheimer-type dementia 
(as opposed to other dementias) has pervaded scientists’ efforts to describe the pathogenesis of 
AD, eventually yielding the amyloid cascade hypothesis. In response to the weaknesses of the 
amyloid cascade hypothesis touched on in the previous section, recent work has sought to 
reevaluate the causes and mechanisms that lead to AD, using other risk factors as a starting-off 
point. Inspired by the identification of a number of cardiovascular conditions as risk factors 
common to AD, metabolic syndrome, and cerebrovascular dementia, a number of researchers 
have endorsed a vascular hypothesis for AD.
17 
 Beginning in the early 1990’s researchers, especially J. C. de la Torre, began to 
synthesize an array of related evidences into a hypothesis to explain AD that incriminates a loss 
of adequate cerebral perfusion as the primary initiator of the AD pathological cascade. Electron 
microscopy had revealed that, compared to age-matched controls, many small blood vessels in 
AD brains were in significantly poorer condition. Studies using imaging scans that can determine 
the rates of glucose metabolism (PET) and oxygen demand (SPECT) had found that these 
parameters are reduced significantly in regions of AD brains that correspond with classic senile 
plaque and NFT pathology; these conditions are also localized to regions which receive less-
than-adequate blood supply. A deficit in glucose transporters in neurons, glia and surrounding 
microvessels, appears in AD, relative to controls. Finally, the concentrations of a number of 
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important biochemicals including proteins, neurotransmitters, and enzymes are lower in AD 
brains.
18 
 In light of this aggregate data, J. C. de la Torre offered the earliest comprehensive 
vascular hypothesis of AD, in which microvascular integrity is compromised over time, leading 
to disturbances in blood flow rates and nutrient delivery, and initiation of reactive gliosis due to 
the release of astroglial mitogens by cells suffering  nutrient deprivation. This astroglial 
proliferation is thought to have a number of downstream effects, including senile plaque and 
NFT formation, decreased inability of the CNS to clear waste products, and other related 
consequences. The pyramidal CA1 neurons appear to be particularly sensitive to these effects 
early on, which coincides with the earliest cognitive symptoms of AD (described in a later 
section).
18 
 Epidemiological studies have shown support for an association between AD and a wide 
range of vascular conditions. Considered chief among these are cerebrovascular disease (stroke), 
cardiac disease, and atherosclerosis. Strokes, in particular cortical microinfarcts and silent 
strokes, can be closely associated with AD, with silent stroke patients in one study showing 
almost twice the risk of developing AD as the baseline. Numerous cardiac conditions show 
strong association with dementia, including AD and a related dementia known as vascular 
dementia (the differentiation of which is less solid in the vascular hypothesis compared to the 
amyloid cascade). These include myocardial infarction, hypertension, and arrhythmias, as well as 
some cardiac surgeries, especially coronary artery bypass graft. Atherosclerosis and its attendant 
sequalae, including hypoperfusion of the brain and damage to endothelial and perivascular cells 
of vessels bearing high atherosclerotic plaque loads, constitute significant risk factors for AD and 
vascular dementia. Furthermore, studies have shown that cognitive impairment associated with 
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chronic cerebral hypoperfusion can be ameliorated following endarterectomy, a procedure in 
which atherosclerotic plaque is surgically removed from the carotid artery.
17
 Collectively, these 
epidemiological results are important to understanding AD, and they must be explained by any 
prospective hypothesis of the disease.   
Alzheimer’s Disease - Clinical Criteria and Diagnostic Methods 
 As our understanding of the biological processes involved in AD constantly evolves in 
response to new research developments, so are the criteria for diagnosing AD clinically, and, as 
will be discussed, potentially pre-clinically. Historically, the most authoritative diagnosis of AD 
has been dependant on the pathological findings of senile plaques and NFTs upon autopsy.
15
 As 
this is, naturally, post-mortem, it is of no functional use to the patient, and so rigorous standards 
for a clinical diagnosis are enumerated by two main sources, the Diagnostic Statistical Manual, 
Fourth Edition (DSMIV) and the National Institute of Neurologic, Communicative Disorders and 
Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA). These 
remain the clinical criteria by which AD is identified. Recently, parallel methods of detecting 
and monitoring AD have been investigated, and include neuroimaging, functional neuroimaging, 
and peripheral biomarkers.
19
 Here, the clinical presentation, criteria, and evolving detection 
methods for AD will be summarized.  
 The first cognitive faculty to be impacted in AD is most often memory – specifically, 
episodic memory and autobiographical memory. Language can also begin to show deficits, 
wherein a patient may be able to maintain the ability to speak clearly but without real substance 
and with subtle aphasia.  Topographical memory impairments also appear, with patients getting 
lost more often, and other daily activities requiring visuospacial faculties, such as dressing and 
hygiene, can suffer.
20
 Additionally, changes in personality and judgment can occur, as well as 
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delusions, hallucinations, and aggression.
15,20
 It is important to note that the earliest 
manifestations can be disparate among the population depending on the specific areas that 
become involved.
15
  
Both the DSM IV criteria and the NINCDS-ADRDA criteria require that a patient present 
with memory impairment accompanied by at least one other deficit from another cognitive 
modality. Each specifically recognizes aphasia (loss of word comprehension, searching for 
words), apraxia (difficulty with visuospatial motor skills like dressing or bathing), agnosia 
(problems recognizing known objects), and dysexecutive functioning (inability to plan and 
execute normal activities) as potential cognitive consequences. These criteria further require that 
these deficits represent a significant impact on a patient’s daily social and/or occupational 
functioning, and present without any other neurological issues identified through a normal 
neurological exam.
15,19
  
Early and accurate diagnosis is naturally of paramount importance in providing patients 
with optimum treatment and management. The above clinical criteria have received some 
criticism (as expressed even in their original proposals) for having less-than-ideal specificity in 
AD diagnosis despite having fairly good accuracy. Estimates of the accuracy of these criteria, as 
measured by validation by neuropathological assessment post-mortem, fall within the range of 
65-96%; specificity estimates, however, are much less encouraging, with a range of 23-88%. As 
the phenotype of AD shares similarities with a number of non-AD dementias, it is not surprising 
that methods relying on clinical presentation might have compromised specificity. Furthermore, 
many of these non-AD dementias now benefit from very sensitive and specific criteria that are 
independent of dementia presentation; for example, diagnoses of primary progressive aphasia 
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can be made before dementia develops. The adjustment of the clinical criteria for AD must be 
likewise improved upon to increase its sensitivity pre-dementia and improve its specificity.
21
 
Various neuroimaging techniques have shown promise in diagnosing AD. The 
assessment of volumetric changes in certain brain regions such as the hippocampus and 
entorhinal cortex by MRI has been evaluated. Results have been positive but still inconclusive, 
as these changes can be non-specific to AD.
19
 Functional neuroimaging techniques, which 
measure the activity of the brain, have also been studied. FDG-PET and 99mTc-HMPAO-
SPECT, which measure glucose metabolism and brain perfusion respectively, have both 
demonstrated efficacy in diagnosing AD and differentiating among dementias, though PET is 
less discriminatory regarding vascular dementia.
21
 Furthermore, the use of PET to detect the 
binding of a ligand, C11-Labeled-Pittsburgh Compound B (PiB), to senile plaques, has been 
intriguing, though at present it suffers from less than ideal specificity (as normal controls may 
exhibit plaque pathology) and accuracy.
15
 These techniques represent one approach to the 
characterization of neurological changes in the brain concurrent with and preceding onset of 
frank AD, and are therefore valuable avenues for the advancement of clinical identification of 
AD. 
Finally, the ability to quantify the concentrations of Aβ peptide, total tau, and 
phosphorylated tau in the cerebrospinal fluid (CSF) has developed into an important tool for 
predicting AD. Aβ peptide is lower in the cerebrospinal fluid of AD patients than in controls, 
though alone is not effective as a diagnostic measure as it correlates poorly with the severity of 
cognitive deficit. High levels of total tau and phosphorylated tau (at wither threonine residue 181 
or 231), however, have been successfully correlative with AD diagnosis.
19
 The evaluation of all 
three markers has shown promising results, with specificities and sensitivities of at least 85% and 
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90% in predicting AD onset within 4 to 6 years.
21
While the assessment of these CSF biomarkers 
have yet to be accepted as routine tests for patients suspected of developing AD by the American 
Academy of Neurology, their value thus far warrants further study.
19 
 As our knowledge of the etiology of AD progresses, so must our clinical 
characterizations of the disease. The application of multiple direct and peripheral methods for the 
diagnosis of AD must continue to be a focus of research, and the characterization of the earliest 
neurological changes associated with the progression to AD has benefitted from similar efforts. 
In assessing the earliest stages of AD, it has been an imperative goal to describe and understand 
the putative transitional condition mild cognitive impairment (MCI).  
Mild Cognitive Impairment 
 While a single definition has remained elusive, MCI generally describes subjective or 
objective cognitive and/or memory deficits that are greater than expected for normal aging but 
fail to impede normal daily activity. Presentation of MCI constitutes a risk factor for developing 
frank AD, with this risk depending on which of a number of subtypes is exhibited. As this stage 
is by definition pre-dementia of any type, including AD, interventions aimed here would 
presumably hold greater therapeutic value than current treatment strategies. Here, the clinical and 
diagnostic criteria of MCI will be described.
21 
 The subset of cognitive complaints of patients diagnosed with MCI forms the dichotomy 
of the MCI subtypes. Amnestic MCI is diagnosed following complaint of memory impairment; 
deficits in other cognitive modalities compose non-amnestic MCI. If the deficit is identified in 
only one area of cognition, it is termed single-domain, and, naturally, if it involves two or more 
areas, it is termed multiple-domain; an individual can have any combination of amnestic, non-
amnestic, single-domain, or multi-domain MCI. For a diagnosis of amnestic MCI to be made, the 
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memory deficit must be significant with respect to age and education matched controls. In 
assessing mental state, it has been recommended that more specific memory tests be employed, 
as performance on typical examinations of mental state for identification of AD (mini-mental 
state examination (MMSE), modified mini mental state examination (3MS), or Kokman Short 
Test of Mental Status) will be close to normal.
19
 Amnestic MCI has been shown to have a higher 
risk for progressing to AD than non-amnestic MCI, though the definitional criteria need further 
refinement before the diagnosis implies that prognosis with adequate specificity and sensitivity. 
This difficulty also applies to clinical trials of treatments aimed at preventing the progression 
from MCI to frank AD, because the cohorts included may not all represent prodromal AD.
21
 
 Given the risks for developing AD posed by MCI, a characterization of the 
neuropathological events occurring in MCI, and thus before the presentation of any dementia, 
has been a priority. Many studies have demonstrated that the brains of MCI subjects examined 
post-mortem display varying degrees of senile plaque and vascular pathology, all occupying the 
range between normal controls and AD subjects, and smaller studies have shown that both MCI 
and early AD brains contain NFT pathology.
21
 These results support the notion that MCI 
represents a transitional phase between normal aging and some terminal condition, including 
AD. This is in spite of the fact that many MCI cohorts have included proportions of subjects for 
whom there was no progression, and in some even a reversal of cognitive decline
 22
; these 
discrepancies are potentially a product of an incomplete understanding of the clinicopathological 
substrates of MCI, including amnestic MCI.  
 Assessing the underlying mechanisms of MCI and its progression to AD is extremely 
important, as with this understanding will come a greater ability to develop and target 
interventions aimed at the pre-dementia stage. One aspect of neurological functioning which has 
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long been studied in AD and is now being investigated in MCI – the integrity of dendritic spines 
– is a crucial part of any model of the disease.  
Dendritic Spines in AD and MCI 
 Along dendritic lengths, the majority of excitatory synapses occur at small 
compartmentalized protrusions of the dendritic membrane called spines. Spines represent a 
substrate for learning and memory, as their number and configuration is dynamic and responsive 
to a number of stimuli. Spines are characterized by a number of shapes, with varying sizes of 
spine necks and heads; spine heads constitute the post-synaptic components of excitatory 
synapses and thus contain receptors for neurotransmission, of which AMPA and NMDA are 
types of interest. Spines have long been known to be affected in AD, and so their assessment in 
and before AD has been extensively described.
23
 Here, the effects of AD and MCI on spines will 
be summarized, followed by a discussion of the sensitivity of these structures and the protein 
mechanisms controlling their development to Aβ oligomers.  
 The loss of dendritic spines, representing a loss of synapses, has been shown to better 
correlate with cognitive decline in AD than do evaluations of senile plaque burden. Through 
electron microscopy studies, immunohistochemical assessments of synaptic protein densities, 
and visualization of neurons through Golgi staining this synaptic loss has been well 
characterized. While the exact mechanism behind these changes is still unclear, studies 
investigating the effects of Aβ peptides on spines via the NMDA receptor, as well as studies 
examining the relative expression of synaptic proteins have provided some groundwork. Aβ 
oligomers have been shown to interact specifically with NMDA receptors (as described in part 
above), and to further cause a reduction in spine density and NMDA number, with the former 
effect requiring the latter.
23
 In one study using human tissue, a reduction in synapse density in 
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the hippocampal CA1 neurons in mild AD, as well as in MCI, was reported. Both showed 
synapse loss relative to non-cognitively impaired controls, with the greater of the two reductions 
seen in mild AD.
24 
 
Measuring synaptic protein expression in AD and MCI, and in different regions of the 
brain, has illustrated one important facet of spine changes in AD: the changes that occur do not 
do so homogeneously. One investigation of the levels of synaptophysin (SYP), synaptogtagmin 
(SYT), and drebrin (DRB) in five regions of the human neocortex (anterior cingulate, superior 
frontal, superior temporal, inferior parietal, and visual), in the tissue of subjects who either had 
sever AD, mild AD, MCI, or no cognitive impairment, found that DRB was differentially 
regulated in MCI in the superior frontal cortex. DRB is a post-synaptic protein associated with 
the generation of spines via modulation of the actin cytoskeleton, as well as the recruitment of 
neurotransmitter receptors to the post-synaptic membrane. DRB was found to be decreased 
uniformly in AD, and in all but the superior frontal cortex, the same was true of MCI. In the 
superior frontal cortex of MCI subjects, DRB levels were elevated relative to both AD and 
normal controls. The elevation of DRB in the superior frontal cortex (a region associated with 
executive functioning) in MCI may explain the relative preservation of executive functioning in 
early AD, and the uniform loss elsewhere may likewise explain the loss of spines and resultant 
cognitive impairment related to those regions.
25 
 
Beyond DRB, the actin cytoskeleton and relevant regulators of its function in the 
formation and support of spines has been shown to be responsive to Aβ oligomers in both 
hippocampal cells in vitro and in mouse models of AD.  The actin cytoskeleton is in part 
regulated by cofilin, a protein which is regulated via phosphorylation by an intermediate kinase 
called LIM kinase. LIM kinase is in turn activated by phosphorylation by p21-activated kinase 1, 
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or PAK1. Cofilin, when unphosphorylated, is active, and disrupts the assembly of actin 
monomers into filaments, which can lead to spine destabilization. PAK’s phosphorylation of 
LIM kinase enables the latter to phosphorylate cofilin, inactivating it and thus supporting spine 
formation. Aβ oligomer has been shown to effect a downregulation of PAK1, thus facilitating the 
dysregulation of cofilin. Furthermore, drebrin was found to be decreased, which reinforces the 
role of Aβ oligomers in effecting dysregulation of upstream actin regulators and the resulting 
spine loss.
26 
 As evidenced by the above discussions, dendritic spine loss, in both correlating highly 
with AD, and in being demonstrated to be the result (at least in part) of AD and MCI specific and 
heterogeneous changes in synaptic protein stoichiometry and Aβ mediated dysregulation of the 
actin cytoskeleton responsible for spine development, should remain a focus of scientific 
attention. As synapses are the substrate for cognitive functioning and memory, understanding 
how spines change and why they do so differently in different regions of the brain will illuminate 
potential targets for future therapeutic strategies.  
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